Author

J. Odegaard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. Alouffi· 2 shared F. Falcone· 2 shared L. Le· 2 shared L. Pennington· 2 shared M. Hsieh· 2 shared R. Zee· 2 shared T. Jardetzky· 2 shared A. Baca· 1 shared

Activity by Year

2017-2018 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Alouffi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

IPSE, a parasite-derived host immunomodulatory protein, is a promising therapeutic for hemorrhagic cystitis

R. Zee, E. C. Mbanefo, L. Le, L. Pennington, J. Odegaard, T. Jardetzky, A. Alouffi, J. Akinwale, F. Falcone, M. Hsieh

This paper demonstrates that H-IPSEH03, a parasite-derived protein, is effective in treating hemorrhagic cystitis by reducing bladder inflammation and promoting urothelial proliferation.

bioRxiv · Aug 25, 2018Immunology

IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways

E. Mbanefo, L. Le, R. Zee, N. Banskota, K. Ishida, L. Pennington, J. Odegaard, T. Jardetzky, A. Alouffi, F. Falcone, M. Hsieh

This study identifies IPSE's mechanism in reducing ifosfamide-induced cystitis by downregulating pro-inflammatory pathways and oxidative stress responses in mouse bladders.

bioRxiv · Aug 3, 2018Immunology

The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients

O. Zill, K. Banks, S. Fairclough, S. Mortimer, J. Vowles, R. Mokhtari, D. R. Gandara, P. C. Mack, J. Odegaard, R. Nagy, A. Baca, H. Eltoukhy, D. Chudova, R. Lanman, A. Talasaz

This study analyzes cfDNA from 21,807 cancer patients to identify actionable genomic alterations and their relationship to treatment and tumor heterogeneity.

bioRxiv · Dec 12, 2017Cancer Biology